Prestige Biologics Co Stock Fundamentals

334970 Stock  KRW 5,330  360.00  6.33%   
Prestige Biologics Co fundamentals help investors to digest information that contributes to Prestige Biologics' financial success or failures. It also enables traders to predict the movement of Prestige Stock. The fundamental analysis module provides a way to measure Prestige Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prestige Biologics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Prestige Biologics Co Company EBITDA Analysis

Prestige Biologics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Prestige Biologics EBITDA

    
  (12.84 B)  
Most of Prestige Biologics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prestige Biologics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Prestige Biologics Co reported earnings before interest,tax, depreciation and amortization of (12.84 Billion). This is 1563.91% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The ebitda for all Republic of Korea stocks is significantly higher than that of the company.

Prestige Biologics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Prestige Biologics's current stock value. Our valuation model uses many indicators to compare Prestige Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prestige Biologics competition to find correlations between indicators driving Prestige Biologics's intrinsic value. More Info.
Prestige Biologics Co is number one stock in return on equity category among its peers. It also is the top company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Prestige Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prestige Biologics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Prestige EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prestige Biologics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prestige Biologics could also be used in its relative valuation, which is a method of valuing Prestige Biologics by comparing valuation metrics of similar companies.
Prestige Biologics is currently under evaluation in ebitda category among its peers.

Prestige Fundamentals

About Prestige Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Prestige Biologics Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prestige Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prestige Biologics Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. The company was founded in 2015 and is based in Cheongju-si, South Korea. Prestige Biologics is traded on Korean Securities Dealers Automated Quotations in South Korea.

Pair Trading with Prestige Biologics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Prestige Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prestige Biologics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Prestige Stock

  0.66207940 Samsung BiologicsPairCorr
  0.62302440 SK BiosciencePairCorr
  0.88326030 Sk BiopharmaceuticalsPairCorr
  0.77298380 ABL BioPairCorr
  0.8144510 Green Cross LabPairCorr

Moving against Prestige Stock

  0.35029780 Samsung CardPairCorr
The ability to find closely correlated positions to Prestige Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prestige Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prestige Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prestige Biologics Co to buy it.
The correlation of Prestige Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prestige Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prestige Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prestige Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Prestige Stock

Prestige Biologics financial ratios help investors to determine whether Prestige Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prestige with respect to the benefits of owning Prestige Biologics security.